2026 Horizons

Life Sciences and Health Care

The life sciences and health care industry entered 2026 in a state of rapid change. Regulation is evolving quickly, technology is more deeply embedded in products and operations, and companies face growing pressure to adapt across global markets. Artificial intelligence is no longer experimental: it is now used throughout the lifecycle of drugs and medical devices – from research and development to approval, manufacturing, and monitoring after launch. Regulators in the U.S., UK, Asia-Pacific region, and Europe are responding by issuing new guidance, using AI in their own reviews, and paying closer attention to consumer‑facing tools such as chatbots, clinical decision support, and digital health applications.

AI and Digital Health

Data, Privacy, and Cybersecurity

Manufacturing and Supply Chain

Geopolitical and Regulatory Changes

M&A, Licensing and Commercial Transactions

Clinical Trials

CTGTs and Rare Disease Therapies

Antitrust, Competition, and Economic Regulation

Global Compliance and Litigation

Doing Business in the EU

Doing Business in APAC

Get in touch

“Hogan Lovells” or the “firm” is an international legal practice that includes Hogan Lovells International LLP, Hogan Lovells US LLP and their affiliated businesses.

The word “partner” is used to describe a partner or member of Hogan Lovells International LLP, Hogan Lovells US LLP or any of their affiliated entities or any employee or consultant with equivalent standing. Certain individuals, who are designated as partners, but who are not members of Hogan Lovells International LLP, do not hold qualifications equivalent to members.

For more information about Hogan Lovells, the partners and their qualifications, see www.hoganlovells.com.

Where case studies are included, results achieved do not guarantee similar outcomes for other clients. Attorney advertising. Images of people may feature current or former lawyers and employees at Hogan Lovells or models not connectedwith the firm.